Stock Markets September 10, 2026 05:12 AM

Genus shares slide after FY26 results show profit beat but weaker revenue and cautious FY27 outlook

Adjusted profits rise but revenue misses consensus and management warns of a first-half FY27 hit to earnings; £60m buyback offers limited support

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
GNS

Genus PLC shares tumbled after the company released preliminary fiscal 2026 results that combined a stronger-than-expected profit performance with a revenue shortfall and a cautious forecast for fiscal 2027. Adjusted operating profit and adjusted profit before tax both rose materially, helped by PIC growth and a milestone payment, yet adjusted revenue fell short of analyst consensus following the deconsolidation of PIC China. Management said FY27 adjusted profit before tax will be weighted to the second half because of near-term challenges across pork and dairy markets. A newly announced £60 million share buyback failed to prevent a pronounced sell-off.

Genus shares slide after FY26 results show profit beat but weaker revenue and cautious FY27 outlook
GNS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Genus reported FY26 adjusted revenue of £658.1 million, down 2% and below the consensus of £668.28 million, largely due to the deconsolidation of PIC China into a new joint venture with Beijing Capital Agribusiness.
  • Adjusted operating profit including joint ventures rose 25% to £116.0 million, aided by PIC growth and a £5.6 million milestone payment; adjusted profit before tax increased 35% to £100.2 million.
  • Management expects FY27 adjusted profit before tax to be second-half weighted because of first-half disease-related issues in North American pork production, low Brazilian pork prices, and subdued global dairy prices; the company announced a £60 million share buyback that did not prevent a sharp share price decline.

Genus PLC shares fell sharply after the British animal genetics group published preliminary results for the fiscal year 2026. The stock declined 6.5% to trade at 2088p following the release, as investors digested a mixed set of numbers and a cautious near-term earnings outlook.

Top-line and drivers

For the fiscal year, Genus reported adjusted revenue of £658.1 million, a 2% decline versus the prior year and below the analyst consensus of £668.28 million. The company attributed much of the top-line contraction to the deconsolidation of PIC China - its Chinese porcine genetics unit - which was moved into a new joint venture with Beijing Capital Agribusiness.

Profitability

On the profitability front, Genus posted a stronger performance. Adjusted operating profit, including results from joint ventures, rose by 25% to £116.0 million. The gain was driven by robust growth at PIC and was supported by a £5.6 million milestone payment from Beijing Capital Agribusiness. Adjusted profit before tax increased 35% to £100.2 million.

Outlook and near-term risks

Management provided cautious guidance for fiscal 2027, saying adjusted profit before tax is expected to be weighted to the second half. The company pointed to several first-half headwinds that underpin this guidance: disease-related challenges affecting North American pork production, weak pork prices in Brazil, and subdued global dairy prices. These factors, it said, will likely depress earnings in the first half of FY27 relative to the second half.

Shareholder return action

Genus also announced a £60 million share buyback programme alongside the results. While the buyback is shareholder-friendly, it did not prevent the market reaction to the revenue shortfall and the conservative FY27 guidance; shares remained well below the intraday peak of 2362p reached earlier in the session.


Market context

The stock moved in a wider UK market environment that had opened against a challenging global backdrop. On Thursday, September 10, London equities were attempting a modest recovery after an earlier sell-off, with investors weighing the effects of rising oil prices, tensions in the Middle East, and renewed inflation concerns. In the prior session, the FTSE 100 had fallen 1.31% and the FTSE 250 dropped 0.99% as Brent crude climbed above $100 a barrel for the first time since July, heightening worries that energy costs could keep inflation elevated and complicate central bank decisions.

Why the stock fell

Investors reacted negatively to the combination of a revenue miss versus consensus, a forward profit outlook leaning on the second half of the year, and an uncertain macro backdrop for UK mid-cap names. Even with record adjusted profits and a material buyback announced, these elements were sufficient to drive a sharp intraday decline in Genus shares, taking the price down from the session high to the level around 2088p at the time of reporting.


Bottom line

Genus reported stronger-than-expected adjusted profits for FY26 but failed to meet revenue expectations after PIC China was deconsolidated into a joint venture. Management signalled that FY27 profits will likely be second-half weighted because of livestock disease in North America, low Brazilian pork prices, and weak global dairy prices. A £60 million buyback was disclosed but did not offset investor concerns, and the stock moved notably lower in a broader market dealing with higher oil prices and geopolitical and inflation-related uncertainties.

Risks

  • Disease-related disruptions to North American pork production could weaken near-term earnings in the livestock genetics sector, directly affecting companies exposed to porcine genetics.
  • Sustained low pork prices in Brazil and subdued global dairy prices could depress revenues and margins for genetics suppliers serving those markets.
  • A challenging macro environment for UK mid-cap stocks - including higher oil prices, geopolitical tensions in the Middle East, and renewed inflation concerns - may amplify share price volatility and constrain market appetite for cyclical agricultural technology and genetics firms.

More from Stock Markets

Volkswagen Estimates Restructuring Will Cost About €16 Billion Sep 10, 2026 Volkswagen Says Restructuring Could Cost About €16 Billion as Cuts and Site Reviews Move Forward Sep 10, 2026 Cooper Companies Shares Plummet After Revenue Miss, Guidance Cut and Strategic Review Halt Sep 10, 2026 Alumis Shares Jump After Positive Psoriasis Data, Insider Buying, and Partnership Focus Sep 10, 2026 Aerospace M&A Accelerates as Jet Output Strengthens Sep 10, 2026